Competition will make weight-loss drugs better, cheaper and bigger
Novo Nordisk and Eli Lilly face a growing number of challengers
Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking remedies for erectile dysfunction and hair loss. Since May it has offered its own version of Wegovy, a blockbuster slimming jab, thanks to a quirk in American law that lets pharmacies replicate some brand-name drugs when there are shortages. Analysts expect that the company will pocket around $145m from its weight-loss drug this year.
This article appeared in the Business section of the print edition under the headline “Pharma frenzy”
Business October 26th 2024
- America’s growing profits are under threat
- Are bosses right to insist that workers return to the office?
- South-East Asia’s stodgy conglomerates are holding it back
- Competition will make weight-loss drugs better, cheaper and bigger
- Memory chips could be the next bottleneck for AI
- How to manage politics in the workplace
- Can Google or Huawei stymie Apple’s march towards $4trn?
From the October 26th 2024 edition
Discover stories from this section and more in the list of contents
Explore the editionDiscover more
Elon Musk’s xAI goes after OpenAI
The fight is turning nasty
How to behave in lifts: an office guide
Life in an elevator
Donald Trump’s victory has boosted shares in private-prison companies
A hard line means hard cash
Gautam Adani faces bribery charges in America
Prosecutors allege one of India’s richest men paid off local officials
Nvidia’s boss dismisses fears that AI has hit a wall
But it’s “urgent” to get to the next level, Jensen Huang tells The Economist
Does Dallas offer a vision of America’s future?
The Texan city embodies the allure of small government